The catalytic deuterodechlorination of aryl/heteroaryl chlorides was developed with a palladium/unsymmetrical NHC system, and the precisely controlled introduction of deuterium into a variety of aryl/heteroaryl compounds was achieved with a high level of efficiency, selectivity, and deuteration degree. This method was also successfully applied to the transformation of bioactive agents even in a gram-scale
Sulfonium ylide formation and subsequent C S bond cleavage of aromatic isopropyl sulfide catalyzed by hemin in aqueous solvent
作者:Xiaojing Yan、Chang Li、Xiaofei Xu、Quan He、Xiaoyong Zhao、Yuanjiang Pan
DOI:10.1016/j.tet.2019.04.035
日期:2019.6
Heme is an abundant and widely existed cofactor for a variety of metalloenzymes, whose broader use is generally impeded by its high instability and poor solubility. Here we report an environment-benign and efficient strategy for the sulfonium ylide formation and subsequent CS bondcleavage of aromatic isopropyl sulfides, which was catalyzed by hemin in assistance of Triton X-100. This aqueous catalytic
Kinetics of α-chlorination of sulphoxides by N-chlorobenzotriazole
作者:Dario Landini、Angela Maia
DOI:10.1039/p29750000218
日期:——
The α-chlorination of aryl methyl and aryl isopropyl sulphoxides with N-chlorobenzotriazole in acetonitrile in the presence of pyridine follows second-order kinetics. The reaction is favoured by electron-donating groups and is subject to a noticeable kinetic isotope effect (KH/KD). On the basis of the kinetic data a common reaction mechanism is proposed for the two series of sulphoxides, involving
在吡啶存在下,在乙腈中用N-氯苯并三唑进行芳基甲基和芳基异丙基亚砜的α-氯化反应遵循二级动力学。该反应受供电子基团的促进,并且受到明显的动力学同位素效应(K H / K D)。根据动力学数据,提出了两个亚砜系列的通用反应机理,其中涉及形成中间体的氯-氧磺酸盐,在速率确定步骤中,该盐在碱的作用下分解成α-氯亚砜。
2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
申请人:Aicher Thomas D.
公开号:US20090156603A1
公开(公告)日:2009-06-18
Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.